PHGE_OUT_1 [2025-04-02 10:03:26 -0400] 2290 Bytes | 632 tokens | Cum: 632 tkns (7.90% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at BiomX (PHGE) which is at 0.57 up from 0.493. So, I pulled together a bunch of data for you to look over real fast. It's still early, 10:03:25 AM on Wed Apr 02, 2025 -0400. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: BiomX (PHGE)
IPO: IPO date unknown
Shares Outstanding: 25,000,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XASE

Here's the first list of news for BiomX:

C1 - Apr-01-25 06:30AM - BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
C2 - Mar-31-25 06:30AM - BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)
C3 - Mar-25-25 06:30AM - BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates
C4 - Mar-19-25 12:35PM - BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
C5 - Feb-26-25 08:00AM - BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million
C6 - Dec-16-24 08:00AM - BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards
C7 - Nov-14-24 06:30AM - BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates
C8 - Nov-12-24 12:20PM - BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on BiomX (PHGE)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

PHGE_OUT_3 [2025-04-02 10:03:27 -0400] 1109 Bytes | 336 tokens | Cum: 970 tkns (12.12% of 8k)
==========================================================================

Showing C2 (chunk 1 of 13): C2:
**BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)**
Date: Mar-31-25 06:30AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/31/3052117/0/en/BiomX-Announces-Positive-Topline-Results-from-Phase-2-Trial-Evaluating-BX211-for-the-Treatment-of-Diabetic-Foot-Osteomyelitis-DFO.html

The Company will host a conference call and webcast today at 9:00 AM ET, followed by a Key Opinion Leader (KOL) event on April 3, 2025, at 11:00 AM ET to discuss the results

NESS ZIONA, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced positive, topline safety and efficacy results from the Company’s DFO Adap

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PHGE_OUT_5 [2025-04-02 10:03:28 -0400] 985 Bytes | 280 tokens | Cum: 1252 tkns (15.65% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T12:44:18Z - Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - First Watch Restauran...
A2 - 2025-04-01T10:59:19Z - BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure...
A3 - 2025-04-01T10:47:19Z - BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure | Taiwan News | Apr. 1, ...
A4 - 2025-04-01T10:37:50Z - BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure...
A5 - 2025-03-31T12:19:32Z - BiomX Reports Positive BX211 Trial Results In Diabetic Foot Osteomyelitis; Plans Phase 2/3 Trial...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

PHGE_OUT_7 [2025-04-02 10:03:33 -0400] 1098 Bytes | 312 tokens | Cum: 1566 tkns (19.57% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - First Watch Restaurant Gr (NASDAQ:FWRG), Delta Air Lines (NYSE:DAL)**Date: 2025-04-01Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/25/04/44584232/ulta-beauty-to-rally-over-15-here-are-10-top-analyst-forecasts-for-tuesdayTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Goldman Sachs cut Genuine Parts Company GPC price target from $133 to $114. Goldman Sachs analyst Kate McShane downgraded the stock from Neutral to Sell. Genuine Parts shares closed at $119.14 on Monday. See how other analysts view this stock. Needham slashed the price target for Vaxcyte, Inc. PCVX from $140 to $90. Needham analyst Joseph Stringe

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PHGE_OUT_9 [2025-04-02 10:03:34 -0400] 1098 Bytes | 288 tokens | Cum: 1942 tkns (24.27% of 8k)
==========================================================================

Showing A1 (chunk 2 of 5): r maintained a Buy rating. Vaxcyte shares closed at $37.76 on Monday. See how other analysts view this stock. Goldman Sachs raised Ulta Beauty, Inc. ULTA price target from $384 to $423. Goldman Sachs analyst Kate McShane upgraded the stock from Neutral to Buy. Ulta Beauty shares closed at $366.54 on Monday. See how other analysts view this stock. TD Securities increased the price target for First Watch Restaurant Group, Inc. FWRG from $21 to $22. TD Securities analyst Andrew Charles upgraded the stock from Hold to Buy. First Watch Restaurant shares closed at $16.65 on Monday. See how other analysts view this stock. HC Wainwright & Co. raised slashed the price target for BiomX Inc. PHGE from $2 to $21. HC Wainwright & Co. analyst Joseph Pantginis maintained a Buy rating. BiomX shares closed at $0.5557 on Monday. See how other analysts view this stock. D. Boral Capital cut Reviva Pharmaceu

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PHGE_OUT_11 [2025-04-02 10:03:35 -0400] 914 Bytes | 296 tokens | Cum: 2240 tkns (28.00% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-23T18:00:00Z - Phage Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight
B2 - 2024-12-20T16:00:00Z - BitMart Research: BMX 2024 Annual Report
B3 - 2024-10-15T11:00:00Z - BiomX Announces a Mandatory Unit Separation
B4 - 2024-08-16T14:55:00Z - UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split
B5 - 2024-07-10T10:32:42Z - BiomX Inc. Announces Stockholder Approval for Conversion of - GlobeNewswire
B6 - 2024-05-30T11:00:00Z - BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PHGE_OUT_13 [2025-04-02 10:03:38 -0400] 909 Bytes | 223 tokens | Cum: 2465 tkns (30.81% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Phage Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/23/3014527/0/en/Phage-Therapies-Clinical-Trial-Pipeline-Shows-Potential-with-Active-Contributions-from-20-Key-Companies-DelveInsight.htmlThe phage therapy market is experiencing significant growth due to the increasing prevalence of antibiotic-resistant infections and the growing interest in alternative treatments. Advances in biotechnology and ongoing research are driving innovation in phage-based therapeutics, offering a promising solution to combat multidrug-resistant pathogens.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PHGE_OUT_15 [2025-04-02 10:03:39 -0400] 1108 Bytes | 282 tokens | Cum: 2818 tkns (35.23% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 8-K Item 7.01 Regulation FD Disclosure.

On March 31, 2025, BiomX Inc., or the Company, issued a press release announcing positive results from its Phase 2 Trial evaluating BX211 for the treatment of Diabetic Foot Osteomyelitis, or DFO, a copy of which is furnished as Exhibit 99.1. ...

S2 - 2025-03-25 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the notes thereto contained e...

S5 - 2025-02-27 8-K Item 1.01 Entry into a Material Definitive Agrmt.

Registered Direct Offering and Concurrent Private Placement

On February 25, 2025, BiomX Inc. (the Company) entered into a securities purchase agreement (the Purchase Agrmt) with certain institutional and accredited inv...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PHGE_OUT_17 [2025-04-02 10:03:43 -0400] 1098 Bytes | 222 tokens | Cum: 3042 tkns (38.02% of 8k)
==========================================================================

Showing S2 (chunk 1 of 6): S2:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the notes thereto contained elsewhere in this Annual Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those discussed in any forward-looking statement because of various factors, including those described in the sections titled Cautionary Statement Regarding Forward-Looking Statements and Risk Factors in this Annual Report.

Overview

We are a clinical stage product discovery company developing products using both natural and engineered phage technologies designed to target and kill

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PHGE_OUT_19 [2025-04-02 10:03:59 -0400] 8201 Bytes | 2140 tokens | Cum: 5266 tkns (65.83% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+-----------------------+
| Volume: 140,782 | Perf Month: -10.23% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+-----------------------+
| Avg Volume: 92.91K | Perf Quarter: -17.27% | Short Float: 0.25% | ROE: -189.64% |
+--------------------+-----------------------+------------------------+-----------------------+
| Rel Volume: 16.58 | Index: - | Short Ratio: 0.34 | ROI: -79.19% |
+--------------------+-----------------------+------------------------+-----------------------+
| RSI (14): 44.81 | Market Cap: 14.47M | Short Interest: 0.03M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+-----------------------+
| ATR (14): 0.08 | Shs Outstand: 18.18M | Beta: 1.55 | EPS Surprise: 141.10% |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA20: -1.50% | Shs Float: 12.71M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA50: -19.61% | Inst Own: 25.55% | Sales past 5Y: 0.00% | Earnings: Mar 25 BMO |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA200: -53.42% | Insider Own: 49.14% | Employees: 57 | |
+--------------------+-----------------------+------------------------+-----------------------+
| Perf Week: 11.30% | Insider Trans: 0.00% | Debt/Eq: 0.40 | |
+--------------------+-----------------------+------------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

No transactions recorded.

Inside Trans: BiomX Inc. (PHGE) by Flynn James E (Unknown Title) on 2025-02-27
- Common Stock: 353249 shares at $0.9306 (I) Footnote: On February 27, 2025, each of Deerfield Private Design Fund V, L.P. ("DPD V") and Deerfield Healthcare Innovations Fund II, L.P. ("HIF II" and together with DPD V, the "Funds" and each a "Fund") exercised its Private Placement Warrant (as defined in the Form 4 filed by the Reporting Persons on July 9, 2024 with respect to the Issuer) for cash in respect of 1,611,864 shares of Common Stock (the "Exercise Shares"), pursuant to a letter agreement, dated as of February 25, 2025 (each an "Inducement Letter Agreement"), between such Fund and the Company. Pursuant to each Inducement Letter Agreement, each such exercise was effected at a reduced exercise price of $0.9306 per share in consideration for the issuance by the Company to such Fund of a new warrant (each, a "New Warrant") to purchase up to 1,611,864 shares of Common Stock (the "New Warrant Shares"). To the extent the exercise of a Private Placement Warrant in accordance with an Inducement Letter Agreement would otherwise have resulted in the issuance of a number of shares of Common Stock in excess of the number of shares of Common Stock that the Funds could acquire without exceeding the beneficial ownership limitations ("Beneficial Ownership Limitation") set forth in the Private Placement Warrants, pursuant to the Inducement Letter Agreement, on February 27, 202 (i) the Company issued to each Fund 353,249 shares of Common Stock (representing the maximum number of shares of Common Stock that each Fund was entitled to receive without exceeding the Beneficial Ownership Limitation), and (ii) in lieu of issuing the remaining 1,258,614 shares of Common Stock for which each Fund exercised its Private Placement Warrant, amended and restated the portion of the Private Placement Warrant exercisable for such excess shares as set forth in the Amended and Restated Warrant (as defined below).
- Common Stock: 353249 shares at $0.9306 (I) Footnote: On February 27, 2025, each of Deerfield Private Design Fund V, L.P. ("DPD V") and Deerfield Healthcare Innovations Fund II, L.P. ("HIF II" and together with DPD V, the "Funds" and each a "Fund") exercised its Private Placement Warrant (as defined in the Form 4 filed by the Reporting Persons on July 9, 2024 with respect to the Issuer) for cash in respect of 1,611,864 shares of Common Stock (the "Exercise Shares"), pursuant to a letter agreement, dated as of February 25, 2025 (each an "Inducement Letter Agreement"), between such Fund and the Company. Pursuant to each Inducement Letter Agreement, each such exercise was effected at a reduced exercise price of $0.9306 per share in consideration for the issuance by the Company to such Fund of a new warrant (each, a "New Warrant") to purchase up to 1,611,864 shares of Common Stock (the "New Warrant Shares"). To the extent the exercise of a Private Placement Warrant in accordance with an Inducement Letter Agreement would otherwise have resulted in the issuance of a number of shares of Common Stock in excess of the number of shares of Common Stock that the Funds could acquire without exceeding the beneficial ownership limitations ("Beneficial Ownership Limitation") set forth in the Private Placement Warrants, pursuant to the Inducement Letter Agreement, on February 27, 202 (i) the Company issued to each Fund 353,249 shares of Common Stock (representing the maximum number of shares of Common Stock that each Fund was entitled to receive without exceeding the Beneficial Ownership Limitation), and (ii) in lieu of issuing the remaining 1,258,614 shares of Common Stock for which each Fund exercised its Private Placement Warrant, amended and restated the portion of the Private Placement Warrant exercisable for such excess shares as set forth in the Amended and Restated Warrant (as defined below).
- Warrants: 1611863 shares at $N/A (I)
- Warrants: 1611863 shares at $N/A (I)
- Warrants: 1258614 shares at $N/A (I)
- Warrants: 1258614 shares at $N/A (I)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: {'value': -17727000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.565
Average Volume: 119130.22
30-Day High: 0.6687
30-Day Low: 0.493

[Detailed Financials: TTM 2024]
- Total Assets: $43,233,000.0
- Total Liabilities: $19,085,000.0
- Total Equity: $24,148,000.0
- Current Assets: $20,520,000.0
- Current Liabilities: $8,267,000.0

[Income Statement: TTM 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 1.47

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $2,111,000.0

[Detailed Financials: FY 2024]
- Total Assets: $43,233,000.0
- Total Liabilities: $19,085,000.0
- Total Equity: $24,148,000.0
- Current Assets: $20,520,000.0
- Current Liabilities: $8,267,000.0

[Income Statement: FY 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 1.47

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $2,111,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

PHGE_OUT_21 [2025-04-02 10:04:03 -0400] 676 Bytes | 167 tokens | Cum: 5752 tkns (71.90% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

PHGE_IN_23 [2025-04-02 10:04:03 -0400] 126 Bytes | 29 tokens | Cum: 5865 tkns (73.31% of 8k)
==========================================================================

====================================
[2025-04-02 10:04:03] # Analysis Completed
Elapsed Time: 38.65 seconds